Axinn Represents Thermo Fisher in $7.2 Billion Acquisition of Patheon
May 17, 2017
Axinn is representing Thermo Fisher Scientific Inc. in its $7.2 billion acquisition of Patheon N.V., a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors. The Axinn team consists of John Harkrider and Mark Alexander.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
GCR Live: Law Leaders Europe 2025
Speaking Engagement
Antitrust
Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
Webinar
Antitrust
AHLA Annual Meeting 2025
Speaking Engagement
Antitrust
SABA North America Annual Conference 2025
Speaking Engagement
Antitrust
Patman Returns … and Retreats Again
Axinn Viewpoints
Antitrust
Axinn Successfully Reunites One of Its Pro Bono Clients, a Former Afghan Army Captain, with His Wife and Four Children
Pro Bono
The Texas v. Blackrock ESG Case: The FTC and DOJ Have Entered the Chat
Axinn Viewpoints
Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
Sponsorship
Antitrust
Washington Lawyers’ Committee for Civil Rights and Urban Affairs – 2025 Wiley A. Branton Awards Luncheon
Sponsorship
Antitrust
What's Happening in Germany and Portugal? Catching Up With International Enforcers at the 2025 Spring Meeting
Podcast
Antitrust